This article was originally published in The Gray Sheet
Executive SummaryCompletes 1.5 mil.-share stock repurchase program. Originally authorized in August 1997 at 500,000 shares, the program was subsequently expanded in 1998 to 1.5 mil. shares. The total cost was $5.6 mil
You may also be interested in...
The US FDA has slapped a partial clinical hold on Ipsen’s palovarotene clinical trials in rare bone disorders in children less than 14 years old, due to bone growth concerns.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced October to November.